AbbVie Inc. (NYSE: ABBV) finished the shortened Christmas Eve session higher, and the stock has been essentially flat in after-hours trading—a setup that puts the focus less on “breaking” headlines and more on positioning, policy risk, and the company’s 2026 catalyst calendar.
ABBV ended the day at $229.89 (+0.48%) and was $229.90 in extended trading around 5:00 p.m. ET. [1]
AbbVie stock price after the bell today (Dec. 24, 2025)
U.S. equities traded on a holiday-shortened schedule today. The NYSE’s calendar shows an early close at 1:00 p.m. ET on Wednesday, Dec. 24, 2025, with Christmas Day (Dec. 25) listed as a market holiday. [2]
Against that backdrop, AbbVie’s trading action was steady and notably “low drama”:
- Close: $229.89 (+0.48%) [3]
- After-hours (around 5:00 p.m. ET): $229.90 (flat) [4]
- Day’s range: $228.98 – $230.80 [5]
- Volume: ~1.74M shares (light for ABBV, consistent with the holiday session) [6]
- 52-week range: $164.39 – $244.81 (ABBV is ~6% below the 52-week high) [7]
What that suggests: into the after-hours window, traders weren’t repricing AbbVie on a new company-specific development. Instead, ABBV behaved like a large-cap pharma “quality” name participating in a calm, liquidity-thin tape.
The broader market context matters more than usual on Christmas Eve
Today’s tape was heavily influenced by the market mood and the calendar.
Reuters reported that U.S. stocks closed at record highs in the shortened session, with the Dow and S&P 500 posting all-time closing records, and noted that trading volume was light heading into the holiday. [8]
This matters for ABBV for two reasons:
- Holiday liquidity can exaggerate moves (especially at the open of the next full session), even when there’s no big headline.
- Large-cap, lower-beta healthcare names often trade more on macro “risk-on/risk-off” flows during these quiet weeks than on day-to-day fundamentals.
“What news moved ABBV today?” The honest answer: very little company-specific news
If you’re looking for a fresh AbbVie press release dated today, there likely isn’t one. AbbVie’s own News Center shows the latest company-posted items dated Dec. 2 and Dec. 1, with no new headline dated Dec. 24 on the front page. [9]
That doesn’t mean there was “nothing to learn” today—it just shifts the weight toward research notes and rolling outlook pieces that investors use to frame the next quarter.
Today’s key analysis on AbbVie: the bull case and the headwinds in one place
One of the more widely circulated Wall Street-style summaries today came via Zacks (republished on Nasdaq) as part of its daily research roundup.
The upbeat take (growth durability post-Humira):
- Zacks pointed to AbbVie’s navigation of Humira’s loss of exclusivity and emphasized that Skyrizi and Rinvoq are “performing extremely well,” helped by approvals in new indications, supporting top-line growth over the next few years. [10]
- The note also highlighted that AbbVie is returning to robust revenue growth in 2025, describing 2025 as only the second year after the U.S. Humira LOE, and underscoring AbbVie’s acquisition activity as a way to strengthen its early-stage pipeline for longer-term growth. [11]
The watch-outs (the market still prices these risks):
- The same Zacks summary flagged headwinds including ongoing Humira LOE impacts, competitive pressure on Imbruvica, and “macro headwinds” for Aesthetics. [12]
How to interpret that tonight:
ABBV is being valued less as “Humira’s successor” and more as a diversified biopharma platform—but investors still want proof that immunology strength can keep offsetting erosion elsewhere, especially as competitive dynamics shift in oncology and discretionary medical aesthetics.
Current Wall Street forecasts: where analysts see ABBV over the next 12 months
Even without a breaking headline today, investors often check the “consensus math” after the bell—especially before a potentially jumpy post-holiday open.
According to StockAnalysis’ compilation:
- Consensus rating: Buy
- Average 12-month price target:$242.28 (roughly mid-single-digit upside from current levels)
- Target range:$190 (low) to $289 (high) [13]
What to do with that information:
Price targets don’t predict tomorrow’s open—but they do show that, broadly, analysts still see ABBV as a “carry + stability + gradual upside” story rather than a high-volatility momentum trade.
Dividend and earnings: the two dates many ABBV holders care about most
For many AbbVie investors, the “before the next market open” checklist is really a calendar checklist.
Dividend snapshot
ABBV’s dividend profile remains a major pillar of the stock’s support:
- Annual dividend: about $6.92/share (roughly ~3% yield, depending on price)
- Next ex-dividend date:Jan. 16, 2026 [14]
Next earnings window
Several market calendars currently point to late January 2026 as the next major catalyst:
- StockAnalysis lists Jan. 30, 2026 as the earnings date (calendar-based). [15]
Investors should still treat the exact day as “subject to confirmation” until AbbVie formally announces.
What to know before the market opens “tomorrow”: Christmas Day is closed, next session is Dec. 26
Because today is Wednesday, Dec. 24, 2025, “tomorrow” is Thursday, Dec. 25 (Christmas Day)—and U.S. stock markets are closed. The next regular U.S. equity session is Friday, Dec. 26. [16]
Adding to potential confusion this year: Reuters also reported earlier that major U.S. exchanges said they would remain open on Dec. 24 and Dec. 26 despite a federal holiday directive for government offices. [17]
Bottom line: you’re not prepping for a Dec. 25 open in ABBV—you’re prepping for the first full, post-holiday session on Dec. 26, when liquidity and positioning can shift quickly.
The pre-open checklist for ABBV ahead of Friday, Dec. 26
Here are the items most likely to matter between now and the next opening print:
1) Watch for policy headlines that hit “big pharma” as a group
Drug pricing remains a sector-wide sensitivity. Reuters recently reported on negotiations and deal frameworks involving multiple major drugmakers around U.S. pricing initiatives, which investors have treated as meaningful “overhang” events for the space. [18]
Even when a headline doesn’t name AbbVie directly, ABBV can move with the group on policy read-through.
2) Expect “thin tape” effects and opening volatility
Reuters emphasized that Christmas Eve trading volume was light across the market. [19]
That often leads to:
- wider spreads,
- quicker gap moves at the open,
- and sharper reactions to routine headlines.
3) Re-anchor on fundamentals: Skyrizi/Rinvoq trajectory vs. weaker pockets
If you see ABBV move without obvious news, remember what’s driving the ongoing debate:
- Durable growth engines: Skyrizi and Rinvoq scale-up and label expansions [20]
- Pressure points: Humira erosion, Imbruvica competition, and aesthetics sensitivity to macro conditions [21]
4) Keep the “income + catalysts” calendar in view
In the next several weeks, ABBV’s story will likely be framed by:
5) Technical context: where ABBV sits right now
ABBV is trading in the upper portion of its 52-week range, but below the peak:
- Current: ~$229.9
- 52-week high: $244.81
- 52-week low: $164.39 [24]
That positioning often attracts two opposing flows:
- profit-taking when rallies stall near prior highs, and
- dip-buying from income/defensive investors when the stock pulls back without a fundamental break.
The takeaway: ABBV is quiet after-hours, but the next full session can still surprise
AbbVie stock didn’t deliver fireworks after the early close on Dec. 24—it delivered stability. ABBV held near $229.9 into extended trading, while the broader market heads into Christmas at record levels and low holiday liquidity. [25]
Going into the next open (Friday, Dec. 26), the “must-know” items aren’t a single breaking headline—they’re the macro tape, policy risk, and the near-term calendar (dividend timing and the late-January earnings window) that can reset sentiment quickly.
This article is for informational purposes only and does not constitute investment advice. Consider your risk tolerance and consult a licensed financial professional for personalized guidance.
References
1. stockanalysis.com, 2. www.nyse.com, 3. stockanalysis.com, 4. stockanalysis.com, 5. stockanalysis.com, 6. stockanalysis.com, 7. stockanalysis.com, 8. www.reuters.com, 9. news.abbvie.com, 10. www.nasdaq.com, 11. www.nasdaq.com, 12. www.nasdaq.com, 13. stockanalysis.com, 14. stockanalysis.com, 15. stockanalysis.com, 16. www.nyse.com, 17. www.reuters.com, 18. www.reuters.com, 19. www.reuters.com, 20. www.nasdaq.com, 21. www.nasdaq.com, 22. stockanalysis.com, 23. stockanalysis.com, 24. stockanalysis.com, 25. stockanalysis.com
